Author Archives: Bruno Quinney

#Brain cancer #Spain #Tumour biology

Study identifies new target in brain metastasis 

A new study into brain metastasis has identified an immune target with translational potential.  The study, conducted by researchers at the Spanish National Cancer Research Centre (CNIO), has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. Read More

#Cancer Research #News

#Nobel Prize #Sonoma Biotherapeutics #Tregs

Meet the researcher: Fred Ramsdell, Nobel winner 

Fred Ramsdell is Founder and Advisor, Sonoma Biotherapeutics and one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). He shares his career highlights with Diana Turner.  DT: Can you tell us what you’re working on at the moment or your most recent area of research?… Read More

#Exclusive Content #Opinion

Cell and gene therapies
#ASGCT #Biotech #Cell and gene therapy

Coave to unveil capsid technology at ASGCT 2026 

Biotechnology company Coave Therapeutics is set to unveil its OneAAV universal capsid at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.  The company will deliver two oral presentations and present two posters at the event, being held 11 – 15 May in Boston, US, showing data… Read More

#News

Cancer immunotherapy
#Asgard Therapeutics #Biotech #Cancer immunotherapy #Tumour biology

Gene-based immunotherapy could reprogramme tumour cells 

Biotechnology company Asgard Therapeutics is set to announce preclinical results showing its gene-based cancer immunotherapy could reprogramme tumour cells.  The company will present data on AT-108, a first-in-class, off-the-shelf cancer immunotherapy, in an oral presentation at the ASGCT Annual Meeting, held from 11-15 May in Boston,… Read More

#News

Patient holding pill in hand
#Clinical trial #Combination therapy #Stroke

Combination therapy pill could reduce stroke risk by 40% 

A single pill low-dose combination therapy could reduce the risk of recurrent stroke by almost 40%, trial results show.  GMRx2, developed by biopharmaceutical company George Medicines, reduced recurrent stroke risk in patients with previous intracerebral haemorrhage (ICH) by 39% compared to placebo, according to results published in the New… Read More

#News

Weight loss concept
#Clinical trial #Obesity #Weight loss

Drug delivers 16% weight loss results in Phase III trial 

A new drug could lead to 16% weight loss in patients and improve metabolic health, Phase III results show.  Survodutide, a dual glucagon/GLP‑1 receptor agonist, has been developed by pharmaceutical company Boehringer Ingelheim for the treatment of adults living with obesity or overweight, without type 2 diabetes. … Read More

#News

#Drug discovery #GLP-1 #MetaVia #Obesity

What will define the winners in a crowded GLP-1 era? 

HH Kim, CEO and President of MetaVia, asks what the next generation of GLP-1 drugs might look like.  Over the past two decades, only a few biotech sectors have experienced a hype cycle as rapid and publicly frenzied as the obesity drug sector. In just over a year, GLP-1s have transformed from a… Read More

#Exclusive Content

Mosquito
#Malaria #Novartis #WHO

WHO prequalifies world’s first antimalarial drug for newborns 

The world’s first and only malaria drug for newborns has been cleared globally, marking a crucial step towards addressing a long-standing gap in malaria care.  Coartem (artemether-lumefantrine) Baby, developed by Medicines for Malaria Venture (MMV) and Novartis, has been prequalified by the World Health Organization (WHO) as the first and only antimalarial… Read More

#News #Regulatory

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Genetics #HIV #University of Oxford

HIV treatment may have changed ‘evolutionary trajectory’ 

Antiretroviral therapy (ART) against HIV may have altered the course of human evolution, research says.  A study led by researchers at the University of Oxford, published in Proceedings of the National Academy of Sciences (PNAS), shows that ART is not only transforming outcomes for people living with… Read More

#News

Great British Pounds, Investment
#BioIndustry Association #Europe #Investment #UK

UK leads European biotech investment, BIA reports 

UK biotech led investment in the European market in the first quarter of 2026, new figures from the BioIndustry Association (BIA) show.  The BIA report shows renewed financing was driven by a rebound in venture capital investment and a broader distribution of funding across companies and stages. … Read More

#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

#CDMO #Japan

Japanese pharma shifting earlier to CDMOs, report says 

Japanese pharma companies are shifting to earlier CDMO outsourcing, Neuland Laboratories has said.  According to the report, pharma companies are engaging contract development and manufacturing organisations (CDMOs) earlier in the development cycle, as increasing complexity in peptide programmes places greater strain on in-house capabilities.  This… Read More

#News

Ovarian cancer cells
#MHRA #Ovarian cancer

MHRA approves clinical trial for ovarian cancer therapy 

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a clinical trial application for a therapy targeting advanced high-grade serous ovarian cancer.  CryptiVax-1001, developed by biotechnology company Epitopea, is an off-the-shelf mRNA therapeutic vaccine. It is designed to drive targeted immune responses using a set of tumour-specific antigens chosen for broad… Read More

#Cancer Research #News #Regulatory

T cells
#AI #Automation / robotics #Oncology #T cell engagers

How AI and robotics designed new cancer therapies

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Angus Sinclair, Chief Scientific Officer at LabGenius Therapeutics. LabGenius is a biotech using AI and robotics to design new cancer therapies, and in vivo efficacy data reveals… Read More

#Featured Podcasts #Podcasts